Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, announces that it has entered into an agreement to acquire Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company pioneering non-opioid, non-IV therapies for sedation for medical procedures in the hospital, outpatient, and in-office settings. Melt’s lead investigational therapy, MELT-300, is a patented, sublingually delivered formulation of a fixed dose of midazolam (3mg) and ketamine (50mg) designed to provide rapid, predictable sedation and analgesia without the need for intravenous administration.
Read the full article: Harrow to Acquire Melt Pharmaceuticals //
Source: https://www.globenewswire.com/news-release/2025/09/26/3156941/0/en/Harrow-to-Acquire-Melt-Pharmaceuticals.html